About CSL Limited (ASX:CSL)
CSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment manufactures, markets and develops plasma therapies (plasma products and recombinants). The Seqirus segment manufactures and distributes non-plasma biotherapeutic products. Seqirus manufactures, sells and distributes a range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. It also manufactures and markets in vitro diagnostic products through Seqirus immunohematology. The CSL Intellectual Property segment is engaged in licensing of intellectual property generated by the Company to unrelated third parties. The Company has facilities in Australia, Germany, Switzerland, the United Kingdom and the United States.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: ASX:CSL
- CUSIP: N/A
- Web: www.csl.com.au/
Average Prices:- 50 Day Moving Avg: A$128.55
- 200 Day Moving Avg: A$128.50
P/E:- Trailing P/E Ratio: 47.41
- P/E Growth: 0.00
Dividend:
Profitability:- Net Margins: 16.35%
- Return on Equity: 34.95%
- Return on Assets: 12.30%
Frequently Asked Questions for CSL Limited (ASX:CSL)
What is CSL Limited's stock symbol?
CSL Limited trades on the ASX under the ticker symbol "CSL."
Who are some of CSL Limited's key competitors?
Some companies that are related to CSL Limited include Grifols, S.A. (GRFS), Jazz Pharmaceuticals PLC (JAZZ), ProMetic Life Sciences (PLI), Theratechnologies (TH), Mirati Therapeutics (MRTX), SIGA Technologies (SIGA), Anavex Life Sciences Corp. (AVXL), XOMA Corporation (XOMA), VBI Vaccines (VBIV), Osiris Therapeutics (OSIR), Protalix Biotherapeutics (PLX), ContraFect Corporation (CFRX), Trillium Therapeutics (TRIL), Concordia International Corp (CXR), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF) and Can Fite Biopharma Ltd (CANF).
Who are CSL Limited's key executives?
CSL Limited's management team includes the folowing people:
- Paul Perreault, Chief Executive Officer, Managing Director, Executive Director
- David Mark Lamont, Chief Financial Officer
- Gordon Naylor, President - Seqirus
- Greg Boss, Executive Vice President, Legal and CSL Group General Counsel
- Karen Etchberger, Executive Vice President - Quality and Business Services
- Bob Repella, Executive Vice President - Global Commercial Operations
- Val Romberg, Executive Vice President of Manufacturing and Planning
- Alan J. Wills, Senior Vice President - Strategy and Business Development
- Andrew Cuthbertson, Chief Scientific Officer, R&D Director
- Laurie Cowan, Senior Vice President - Human Resources
MarketBeat Community Rating for CSL Limited (ASX CSL)MarketBeat's community ratings are surveys of what our community members think about CSL Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for CSL Limited (ASX:CSL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Consensus Price Target History for CSL Limited (ASX:CSL)
Analysts' Ratings History for CSL Limited (ASX:CSL)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for CSL Limited (ASX:CSL)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for CSL Limited (ASX:CSL)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for CSL Limited (ASX:CSL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for CSL Limited (ASX:CSL)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for CSL Limited (ASX:CSL)
Latest Headlines for CSL Limited (ASX:CSL)
| Source: |
|
